ERBB2 and breast carcinoma: Datopotamab deruxtecan (brand name Datroway) was granted FDA approval on 17 January 2025, for adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-negative breast cancer who have previously undergone endocrine therapy and chemotherapy for advanced disease [95,96].